Tropical Disease Foundation, Makati City, Philippines.
Int J Tuberc Lung Dis. 2012 Oct;16(10):1326-30. doi: 10.5588/ijtld.12.0038. Epub 2012 Aug 3.
The high prevalence of multidrug-resistant tuberculosis (MDR-TB) in the Philippines is a challenge for the National TB Programme.
To assess patterns of drug resistance and screening outcomes among MDR-TB suspects evaluated from 2003 to 2008 at DOTS-Plus clinics in the Philippines.
Descriptive study of 4897 consecutive patients with suspected MDR-TB.
The median time from the first visit until a diagnosis of drug-resistant TB was 132 days (IQR 110-166 days). Among patients screened for MDR-TB, the most frequent resistance pattern among those previously treated in DOTS facilities was resistance to isoniazid (INH) and rifampicin (RMP). Resistance to INH+RMP plus fluoroquinolones was the most common pattern among those who had failed Category II treatment and patients treated by non-DOTS facilities. Among patients with MDR-TB, 57% ultimately received appropriate treatment with second-line drugs. The remaining 43% were lost to follow-up (25%), died (14%) or refused treatment (4%).
Resistance to INH+RMP is the most frequent resistance pattern among patients referred from DOTS clinics in the Philippines for suspected MDR-TB. Initial use of standard regimens based on national survey data and quick uptake of new rapid molecular resistance tests may be useful to reduce diagnostic delays and expedite treatment for drug-resistant TB.
菲律宾耐多药结核病(MDR-TB)的高患病率给国家结核病规划带来了挑战。
评估 2003 年至 2008 年期间在菲律宾 DOTS-Plus 诊所评估的疑似耐多药结核病患者的耐药模式和筛查结果。
对 4897 例连续疑似耐多药结核病患者进行描述性研究。
从首次就诊到确诊耐药性结核病的中位时间为 132 天(IQR 110-166 天)。在筛查耐多药结核病的患者中,在 DOTS 设施中接受过治疗的患者中最常见的耐药模式是异烟肼(INH)和利福平(RMP)耐药。在失败的 II 类治疗和非 DOTS 设施治疗的患者中,INH+RMP 加氟喹诺酮类耐药最常见。在耐多药结核病患者中,57%最终接受了二线药物的适当治疗。其余 43%失访(25%)、死亡(14%)或拒绝治疗(4%)。
INH+RMP 耐药是菲律宾 DOTS 诊所转诊的疑似耐多药结核病患者中最常见的耐药模式。根据国家调查数据初始使用标准方案和快速采用新的快速分子耐药检测可能有助于减少诊断延误并加快耐药结核病的治疗。